Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Gen Sheng Wu"'
Autor:
Joshua E Allen, Gabriel Krigsfeld, Luv Patel, Patrick A Mayes, David T Dicker, Gen Sheng Wu, Wafik S El-Deiry
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/fc6b85f6734f493ba36e3a76e182456c
Autor:
Mohammed Hafiz Uddin, Jun-Ying Zhou, Julio Pimentel, Steve M. Patrick, Seongho Kim, Malathy P. Shekhar, Gen Sheng Wu
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) are currently being used for treating breast cancer patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic diseases. Despite durab
Externí odkaz:
https://doaj.org/article/b87f14cd879b42a5aa08d654566b9494
Autor:
Ambikai Gajan, Ashapurna Sarma, Seongho Kim, Katherine Gurdziel, Gen Sheng Wu, Malathy P. Shekhar
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Poly-(ADP)-ribose polymerase inhibitors (PARPi) and platinum-based drugs are promising therapies for triple negative breast cancers (TNBC) with BRCA1 or BRCA2 loss. PARPi(s) show better efficacies when combined with platinum-based therapy, however, a
Externí odkaz:
https://doaj.org/article/6e33208bd04f48508bab5d32876b0fe2
Publikováno v:
PLoS ONE, Vol 5, Iss 4, p e10226 (2010)
The mechanism of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance in cancer cells is not fully understood. Here, we show that the Akt survival pathway plays an important role in TRAIL resistance in human cancer cells. Specif
Externí odkaz:
https://doaj.org/article/e0bbf78547014e968a21736e46836138
Publikováno v:
Molecular Carcinogenesis. 62:135-144
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that lacks targeted therapies. Previous studies have shown that TNBC cells are highly sensitive to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), maki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df9befd7b3953bb7b36a811421fac7e6
https://doi.org/10.1002/mc.23471
https://doi.org/10.1002/mc.23471
Autor:
Guido Kroemer, Maria Castedo, Jean-Charles Soria, Murat Saparbaev, Philippe Dessen, Catherine Brenner, Gen Sheng Wu, Kimitoshi Kohno, Parviz Behnam-Motlagh, Pauline Garcia, Abdul Qader Sukkurwala, Delphine Lissa, Cédric Oréar, Philippe Girard, Angélique Robin, Monique Talbot, David Pierre Enot, Justine Guegan, Ibtissam Talhaoui, Laura Senovilla, Oliver Kepp, Ken André Olaussen, Julien Adam, Lorenzo Galluzzi, Ilio Vitale, Judith Michels
PDF file - 490K, Supplementary Table S1. Systematic comparison of the effects of CDDP and PARP inhibitors on cancer cell lines used in this study. Supplementary Figure S1. Generation and characterization of CDDP-resistant human NSCLC cell clones. Sup
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65cc071c79c2ef3428fba45e85da2ba9
https://doi.org/10.1158/0008-5472.22399542.v1
https://doi.org/10.1158/0008-5472.22399542.v1
Autor:
Avraham Raz, Michael A. Tainsky, Stephen P. Ethier, Ricardo V. Lloyd, Wilma L. Lingle, Fergus J. Couch, Judith Abrams, Huixiang Li, Yongjun Guo, Gen Sheng Wu, Zeng Quan Yang, Yi Wang, Tirza Raz, Victor Hogan, Larry Tait, Young Suk Jung, Ann G. Schwartz, Pratima Nangia-Makker, Vitaly Balan
Supplementary Tables 1-2 from Racial Disparity in Breast Cancer and Functional Germ Line Mutation in Galectin-3 (rs4644): A Pilot Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::643bb7a93e4a2a1fcd8b9f97d4209ef3
https://doi.org/10.1158/0008-5472.22375737
https://doi.org/10.1158/0008-5472.22375737
Publikováno v:
Molecular Carcinogenesis. 62
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8aacb783be3e2a5c02fab690b5199ff
https://doi.org/10.1002/mc.23508
https://doi.org/10.1002/mc.23508
Publikováno v:
Cancers. 15:2752
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that selectively induces apoptosis in tumor cells without harming normal cells, making it an attractive agent for cancer therapy. TRAIL induces a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e278f970ca82ee73553db98fe4ca561d
https://doi.org/10.3390/cancers15102752
https://doi.org/10.3390/cancers15102752
Autor:
Haixing Wang, Qi Song, Gen Sheng Wu, Herui Wang, Chen Xu, Zhengping Zhuang, Jie Huang, Dongxian Jiang, Jieakesu Su, Jing Cui, Qi Zhang, Yingyong Hou
Publikováno v:
Cancers
Cancers, Vol 13, Iss 4766, p 4766 (2021)
Cancers; Volume 13; Issue 19; Pages: 4766
Cancers, Vol 13, Iss 4766, p 4766 (2021)
Cancers; Volume 13; Issue 19; Pages: 4766
Simple Summary Paclitaxel-based chemotherapy has been introduced to treat esophageal squamous cell carcinoma. While its initial efficacy has been clinically established, the development of resistance is inevitable. To understand the paclitaxel resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e412270bec56d4a9e15c47bdb2a72afa
http://europepmc.org/articles/PMC8507542
http://europepmc.org/articles/PMC8507542